Viewing Study NCT06134193

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:04 AM
Ignite Modification Date: 2026-02-10 @ 8:21 AM
Study NCT ID: NCT06134193
Status: UNKNOWN
Last Update Posted: 2023-11-18
First Post: 2023-11-12
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma View
None Intrahepatic Cholangiocarcinoma View
None Gallbladder Cancer View
None Surufatinib View
None Angiogenesis Inhibitors View
None Tislelizumab View
None Antineoplastic Agents, Immunological View
None Immunotherapy View
Keywords: